Ticagrelor

Question 1

Ticagrelor Class

Answer 1

Platelet Aggregration Inhibitor

Question 2

Ticagrelor Description

Answer 2

An inhibitor of platelet function

Question 3

Ticagrelor Presentation

Answer 3

90mg Tablets

Question 4

Ticagrelor Administration

Answer 4

Orally (PO)

Question 5

Ticagrelor Indications

Answer 5

Identification of STEMI if transporting to PPCI

Question 6

Ticagrelor Contra-indications

Answer 6

Hypersensitivity to the active substance (Ticagrelor) or to any of the excipients
Active Pathological Bleeding
Hx of Intracranial Haemorrhage
Moderate to Severe Hepatic Impairment

Question 7

Ticagrelor Dose

Answer 7

Adult: Loading Dose of 180mg PO

Paed: Not Indicated

Question 8

Ticagrelor Pharmacology

Answer 8

Ticagrelor is a selective ADP receptor antagonist acting on the P2Y12 ADP-receptor that can prevent ADP-mediated platelet activation and aggregation.
Ticagrelor is orally active, and reversibly interacts with the platelet P2Y12 ADP-receptor.
Ticagrelor does not interact with the ADP binding site itself, but interacts with platelet P2Y12 ADP-receptor to prevent signal transduction.

Question 9

Ticagrelor Side Effects

Answer 9

Dyspnoea
Epistaxis
GI Haemorrhage
Subcutaneous or Dermal Bleeding
Bruising and Procedural site Haemorrhage.

Uncommon:
Intracranial Bleeding
Elevations in serum creatinine and uric acid levels

Question 10

Ticagrelor Additional Info

Answer 10

Authorised to administer 180mg Ticagrelor following identification of STEMI and Medical Practitioner Instruction.
If patient has been loaded with an anti-platelet medication (other than Aspirin), prior to arrival, the patient should not have Ticagrelor administered